Physician profile
Quentin Emerson
NPI 1427065341
$5,136.42
in general payments reported to CMS, 2019-2025
25 companies · $681 in 2025
The $681 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $450 · 2021: $756 · 2022: $766 · 2023: $679 · 2024: $759 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,074 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.99 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,499.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $884.66 | 2020-2025 | Repatha, Otezla, Repatha |
| Kci USA, INC. | $471.81 | 2019 | |
| Amarin Pharma, INC. | $439.96 | 2019-2021 | |
| Lilly USA, LLC | $271.38 | 2020-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $252.51 | 2023-2025 | Auvelity |
| Abbvie INC. | $244.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.75 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $129.15 | 2019-2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $128.22 | 2020-2024 | Trintellix |
| Pfizer INC. | $99.51 | 2019-2025 | |
| Smith+Nephew, INC. | $79.00 | 2021-2024 | Grafix Pl, Collagenase Santyl |
| Otsuka America Pharmaceutical, INC. | $65.47 | 2021-2025 | Abilify Maintena, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.93 | 2022-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $57.07 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.59 | 2022-2023 | |
| Abbott Laboratories | $52.63 | 2021-2022 | |
| Organogenesis INC. | $44.62 | 2024 | |
| Verity Pharmaceuticals INC. | $29.37 | 2024 | Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.66 | 2024 | Caplyta |
| Shire North American Group INC | $19.61 | 2019 | |
| Sumitomo Pharma America, INC. | $19.37 | 2023 | Gemtesa |
| Astellas Pharma US INC | $19.23 | 2021 | |
| Reprise Biomedical, INC. | $18.51 | 2025 | Miro3d |
| Janssen Pharmaceuticals, INC | $16.78 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quentin Emerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.